{"schema_version":"secwatch.filing_event.v1","accession":"0001682852-25-000073","form_type":"8-K","ticker":"MRNA","cik":"0001682852","company_name":"Moderna, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.140127+00:00","generated_at":"2026-05-16T23:47:18.018142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Moderna Q3 net loss $200M, revenue $1.0B down 45% YoY; narrows 2025 guidance","bullets":["Q3 revenue $1.0B (down 45% YoY); net loss $(0.51)/share vs. EPS $0.03 in Q3 2024.","2025 revenue range narrowed to $1.6-2.0B; GAAP opex cut by $0.7B to $5.2-5.4B.","Year-end cash target raised by $0.5-1.0B to $6.5-7.0B; Q3-end cash $6.6B.","COVID vaccine sales $971M; RSV mRESVIA sales $2M; mNEXSPIKE launched in US.","Discontinues congenital CMV program after Phase 3 missed primary endpoint; norovirus study extends."],"urls":{"canonical":"https://secwatch.observer/filing/0001682852-25-000073","json":"https://secwatch.observer/filing/0001682852-25-000073.json","markdown":"https://secwatch.observer/filing/0001682852-25-000073.md","text":"https://secwatch.observer/filing/0001682852-25-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/0001682852-25-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/mrna-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:47:18.018142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}